Pondicherry Journal of Nursing

Register      Login

VOLUME 15 , ISSUE 3 ( July-September, 2022 ) > List of Articles


Extensively Drug Resistance Tuberculosis with Bedaquiline Toxicity: A 2-year Case Report

Anbueswari Kanagaraj, Puvaneswari Kanagaraj

Keywords : Bedaquiline, Bedaquiline toxicity, Extensively drug resistance tuberculosis, Mycobacterium tuberculosis, Multidrug-resistant tuberculosis

Citation Information : Kanagaraj A, Kanagaraj P. Extensively Drug Resistance Tuberculosis with Bedaquiline Toxicity: A 2-year Case Report. 2022; 15 (3):62-64.

DOI: 10.5005/jp-journals-10084-13148

License: CC BY-NC 4.0

Published Online: 31-12-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Tuberculosis (TB) is a contagious disease that usually attacks the lungs and spreads to others organs also. In the twentieth century, TB was a leading cause of death in the USA. Tuberculosis mostly affects adults in their most productive years. However, all age-groups are at risk. Over 95% of cases and deaths are in developing countries. In 2020, 86% of new TB cases occurred in the 30 high TB burden countries. The following eight countries accounted for two-thirds of the new TB cases: India, China, Indonesia, Philippines, Pakistan, Nigeria, Bangladesh, and South Africa. A latent or active TB infection can also be drug resistant. In some cases, more severe drug resistance can develop. Multidrug-resistant tuberculosis (MDR-TB) remains a public health crisis and a health security threat. Only about one in three people with drug-resistant TB accessed treatment in 2020. Without good support, treatment adherence is more difficult in tuberculosis.

  1. World Health Organization, Geneva. Global Tuberculosis Report 2016. Available at: www.who.int/tb/publications/global_report. Accessed on: 19 December 2017.
  2. Ministry of Health and Family Welfare, Government of India. India TB Report 2022: Coming Together to End TB Altogether. Ministry of Health and Family Welfare Government of India. Accessed on: 18 August 2022.
  3. de Araújo–Filho JA, Vasconcelos AC Jr, de Sousa EM, da Silveira C, Ribeiro E, Kipnis A, et al. Extensively drug-resistant tuberculosis: A case report and literature review. Braz J Infect Dis 2008;12(5):447–452. DOI: 10.1590/S1413-86702008000500019.
  4. Cegielski JP. Multidrug-resistant tuberculosis in the end tuberculosis era. Peru Med Exp Salud Publica 2018;35(1):110–117. DOI: 10.17843/rpmesp.2018.351.3618.
  5. Seung KJ, Keshavjee S, Rich ML. Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med 2015;5(9):a017863. DOI: 10.1101/cshperspect.a017863.
  6. Salfinger M, Migliori GB. Bedaquiline: 10 years later, the drug susceptibility testing protocol is still pending. Eur Respir J 2015;45:317–321. DOI: 10.1183/09031936.00199814.
  7. World Health Organization, Geneva. The use of bedaquiline in the treatment of multi drug resistant tuberculosis: Interim policy. Geneva: World Health Organization 2013. Available at: http://www.who.int/tb/challenges/mdr/bedaquiline/en. Accessed on: December 2021.
  8. World Health Organization, Geneva. Rapid communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). 2018. Available at: https://www.who.int/publications/i/item/WHO-CDS-TB-2018.18. Accessed on: 24 April 2019.
  9. World Health Organization, Geneva. WHO announces updated definitions of extensively drug-resistant tuberculosis 2021. Accessed on: 10 August 2022.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.